Nuclear medicine communications
-
Meta Analysis
Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism.
Standard therapy for patients with hypothyroidism is replacement with synthetic thyroxine (T4). However, thyroxine plus triiodothyronine (T3) replacement therapy resulted in marked improvements in several items of the Profile of Mood States and in a few indices of psychometric function and quality of life. The adequacy of thyroxine alone versus thyroxine plus triiodothyronine to treat hypothyroidism has yielded conflicting results. ⋯ In conclusion, on the basis of data from recent studies, we conclude that combined T4 and T3 treatment does not improve well-being, cognitive function, or quality of life compared with T4 alone. T4 alone may be beneficial in improving psychological or physical well-being. According to the current evidence, T4 alone replacement may remain the drug of choice for hypothyroid patients.
-
Meta Analysis
Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis.
The aim of this study was to evaluate the diagnostic accuracy of 18F-fluorodeoxyglucose-PET (FDG-PET) and FDG-PET/computed tomography (CT) in the detection of recurrent or metastatic differentiated thyroid carcinoma (DTC) that was not identified by radioiodine whole-body scintigraphy (WBS). ⋯ FDG-PET is especially effective in detecting patients with elevated thyroglobulin levels and normal radioiodine WBS; FDG-PET/CT is a more sensitive method in the follow-up of thyroid cancer recurrence or metastases, particularly in those with negative WBS.